| Next 10 |
Stock Information
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
MENU
DCPH
DCPH Quote
DCPH Short
DCPH News
DCPH Articles
DCPH Message Board
Get DCPH Alerts
News, Short Squeeze, Breakout and More Instantly...
RECENT DCPH NEWS
-
Deciphera Pharmaceuticals ( DCPH ) announced that it had achieved positive results in a phase 3 study , using its drug ripretinib to treat patients with fourth-line and fifth-line plus gastrointestinal stromal tumors ((GIST)). With these latest results, the biotech holds the potential to ...
-
Shares of Deciphera Pharmaceuticals (DCPH) have risen by just 1% since my September 2018 article suggested initiating a pilot position in the near term and accumulating weakness. To be fair, I had thought ESMO data for DCC-2618 would boost shares and instead they lost nearly half their value...
-
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced registered underwritten public offering. 10,810,810 shares of the Company’s c...
DCPH News and Press, Deciphera Pharmaceuticals Inc.
-
Deciphera Pharmaceuticals ( DCPH ) announced that it had achieved positive results in a phase 3 study , using its drug ripretinib to treat patients with fourth-line and fifth-line plus gastrointestinal stromal tumors ((GIST)). With these latest results, the biotech holds the potential to ...
-
Shares of Deciphera Pharmaceuticals (DCPH) have risen by just 1% since my September 2018 article suggested initiating a pilot position in the near term and accumulating weakness. To be fair, I had thought ESMO data for DCC-2618 would boost shares and instead they lost nearly half their value...
-
Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced registered underwritten public offering. 10,810,810 shares of the Company’s c...
-
On Wednesday evening, Deciphera Pharmaceuticals, Inc. ( DCPH ) announced a $400 million capital raise consisting of 10,810,810 shares priced at $37.00 with an underwriter option for an additional $60 million worth of shares. This was double the initial proposed offering of $200 million. I ...
-
Deciphera Pharmaceuticals (NASDAQ: DCPH ) prices its public offering of ~10.8M common shares at $37 per share. Underwriters over-allotment is an additional ~1.6M shares. Closing date is August 19. More news on: Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
-
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the pricing of its previously announced registered underwritten public offering of 10,810,810 shares of its common stock at ...
-
August 14, 2019 Palm Beach, FL – August 14, 2019 – People with cellulite are not as happy as those without cellulite. That may seem to be self-evident, but now it is supported by studies. One such report, a study published by Surgical and Cosmetic Dermatology, fo...
-
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the commencement of a registered underwritten public offering of $200.0 million in shares of its common stock. In addition, ...
-
Gainers: Mmtec (NASDAQ: MTC ) +346% . Deciphera Pharmaceuticals (NASDAQ: DCPH ) +87% . PEDEVCO (NYSEMKT: PED ) +40% . Mustang Bio (NASDAQ: MBIO ) +24% . OptiNose (NASDAQ: OPTN ) +22% . LSC Communications (NYSE: LKSD ) +21% . Foamix Pharmaceuticals (NASDAQ: FOMX ) +18% . Jumia ...
-
Deciphera Pharmaceuticals (NASDAQ: DCPH ) +121% on positive late-stage ripretinib data . More news on: Deciphera Pharmaceuticals, Inc., DelMar Pharmaceuticals, Inc., Alcentra Capital Corporation, Stocks on the move, Read more ...
